Navigation Links
FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Date:5/23/2011

TARRYTOWN, N.Y. May 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that it has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee Meeting to be held on June 17, 2011 to discuss the Company's Biologics License Application (BLA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  Under Section 505 of the Federal Food, Drug, and Cosmetic Act, absent special circumstances, all new chemical entities, such as VEGF Trap-Eye, are referred to an advisory committee for review.

Regeneron submitted a Biologics License Application for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under priority review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011.

Further information on the advisory committee meeting can be found in the Federal Register at

http://www.accessdata.fda.gov/scripts/oc/ohrms/advdisplay.cfm

About VEGF Trap-EyeVascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

VEGF Trap-Eye is a fully human fusion protein, consisting of soluble VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  VEGF Trap-Eye is a specific and highly potent blocker of these growth factors.  VEGF Trap-Eye is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of the neovascular form of age related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.  Bayer plans to file regulatory submissions in Europe in the second quarter of 2011.

Bayer HealthCare will market VEGF Trap-Eye outside the United States, where the companies will share equally the profits from any future sales of VEGF Trap-Eye.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended March 31, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Third Quarter 2011 Financial Results Conference Call; May 10, 2011 at 11:30 A.M. Eastern
2. Volcano Corporation Schedules First Quarter Conference Call, Webcast
3. WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release
4. MSA Schedules First Quarter Earnings Webcast
5. Roper Industries Reschedules First Quarter 2011 Financial Results Conference Call
6. Generex Schedules Press Conference & Investor Call for March 30th to Discuss Managements Strategic Development Plan for Future Growth
7. Bacterin International Holdings, Inc. Schedules Conference Call to Present Fourth Quarter and Full Year 2010 Financial Results
8. China Botanic Reschedules Fiscal First-Quarter 2011 Earnings Release and Conference Call for March 17, 2011 at 9:00 a.m. EDT
9. Varian Medical Systems Schedules Second Quarter FY2011 News Release and Conference Call
10. China Botanic Schedules Conference Call to Discuss FY 2011 First Quarter Results
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017  The particle ... million by 2021 from USD 275.9 million in ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... spending on pharmaceutical R&D, and growth in manufacturing ... the market growth for particle counters. On the ...
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... 2016, provides drug pricing data and benchmarks in the global Autism ... What are the key drugs marketed for ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology:
(Date:2/24/2017)... Princeton, NJ (PRWEB) , ... February 24, 2017 ... ... organization that provides business development, education, networking and recognition opportunities as well as ... at Bell Works in Holmdel, NJ on February 23. The Council's Innovation ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly ... Dyer started as the Chairman of the Management Committee when IFN was originally ... including the recruitment of investor/owners and development of the business plan. He became ...
(Date:2/24/2017)... Charlevoix, MI (PRWEB) , ... February 24, 2017 ... ... venue in Charlevoix, once again hosted their Military Wedding Giveaway, with the ... be hosted by Castle Farms with services generously donated from local vendors: A ...
Breaking Medicine News(10 mins):